A carregar...
Publicação
Probioxy: redefining the treatment landscape of inflammatory bowel disease - exit strategy
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 919.94 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
ProbiOxy is a biopharma start-up with a vision to develop the first probiotic treatment
that effectively helps patients suffering from Inflammatory Bowel Disease relieve their
symptoms and experience a transformative shift in their quality of life. Its strategic approach
evolves around obtaining initial funding, licensing intellectual property, advancing through pre clinical and clinical trials, growing the patent portfolio, developing the product pipeline, and
ultimately exiting through acquisition by a prominent pharmaceutical entity. Other important
aspects of implementing such a business are preparing and managing the acquisition, and
having a contingency plan in place.
Descrição
Palavras-chave
Science-based entrepreneurship Probiotics Ibd Emerging treatments Exit strategy Exit market M&A Positioning for acquisition Contingency plan Transaction value